Becton, Dickinson and Company (NYSE: BDX) Stock Competitors & Peer Comparison

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ISRG has a market cap of 137.9B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ISRG trades at $390.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ISRG's P/E ratio is 40.57. In terms of profitability, BDX's ROE is +0.04%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, BDX is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ISRG's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while BDXA trades at $59.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BDX's ROE is +0.04%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BDXA's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, MDLN has a market cap of 29.5B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while MDLN trades at $34.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas MDLN's P/E ratio is 25.56. In terms of profitability, BDX's ROE is +0.04%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, BDX is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MDLN's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, WST has a market cap of 24.4B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while WST trades at $346.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas WST's P/E ratio is 43.47. In terms of profitability, BDX's ROE is +0.04%, compared to WST's ROE of +0.19%. Regarding short-term risk, BDX is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for BDX.Check WST's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while HOLX trades at $76.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BDX's ROE is +0.04%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDX is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BDX.Check HOLX's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, SOLV has a market cap of 15B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while SOLV trades at $86.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas SOLV's P/E ratio is 12.24. In terms of profitability, BDX's ROE is +0.04%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, BDX is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for BDX.Check SOLV's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, COO has a market cap of 14.6B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while COO trades at $75.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas COO's P/E ratio is 16.47. In terms of profitability, BDX's ROE is +0.04%, compared to COO's ROE of +0.03%. Regarding short-term risk, BDX is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check COO's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while BDXB trades at $48.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BDX's ROE is +0.04%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BDXB's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, BAX has a market cap of 13.4B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while BAX trades at $25.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas BAX's P/E ratio is 12.46. In terms of profitability, BDX's ROE is +0.04%, compared to BAX's ROE of -0.17%. Regarding short-term risk, BDX is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BAX's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, RGEN has a market cap of 9.5B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while RGEN trades at $169.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas RGEN's P/E ratio is 93.91. In terms of profitability, BDX's ROE is +0.04%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RGEN's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, AVTR has a market cap of 9.1B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while AVTR trades at $13.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas AVTR's P/E ratio is 15.90. In terms of profitability, BDX's ROE is +0.04%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BDX is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AVTR's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ATR trades at $131.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ATR's P/E ratio is 23.05. In terms of profitability, BDX's ROE is +0.04%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BDX is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ATR's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while BLCO trades at $17.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas BLCO's P/E ratio is 26.12. In terms of profitability, BDX's ROE is +0.04%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BDX is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BLCO's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, TFX has a market cap of 5.9B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while TFX trades at $133.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas TFX's P/E ratio is 15.21. In terms of profitability, BDX's ROE is +0.04%, compared to TFX's ROE of -0.32%. Regarding short-term risk, BDX is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check TFX's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, STVN has a market cap of 5.8B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while STVN trades at $21.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas STVN's P/E ratio is 32.33. In terms of profitability, BDX's ROE is +0.04%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STVN's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, MMSI has a market cap of 5.4B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while MMSI trades at $89.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas MMSI's P/E ratio is 22.95. In terms of profitability, BDX's ROE is +0.04%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MMSI's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ICUI has a market cap of 4.6B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ICUI trades at $182.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ICUI's P/E ratio is 22.79. In terms of profitability, BDX's ROE is +0.04%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, BDX is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ICUI's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, NVST has a market cap of 4.5B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while NVST trades at $27.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas NVST's P/E ratio is 18.81. In terms of profitability, BDX's ROE is +0.04%, compared to NVST's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NVST's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, PLSE has a market cap of 3.2B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while PLSE trades at $46.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas PLSE's P/E ratio is -39.65. In terms of profitability, BDX's ROE is +0.04%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, BDX is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BDX.Check PLSE's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ATRC has a market cap of 2.3B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ATRC trades at $44.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ATRC's P/E ratio is 1390.37. In terms of profitability, BDX's ROE is +0.04%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ATRC's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, XRAY has a market cap of 2.2B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while XRAY trades at $11.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas XRAY's P/E ratio is 7.83. In terms of profitability, BDX's ROE is +0.04%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, BDX is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check XRAY's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while LMAT trades at $82.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas LMAT's P/E ratio is 30.33. In terms of profitability, BDX's ROE is +0.04%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BDX is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LMAT's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, BLFS has a market cap of 1.7B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while BLFS trades at $35.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas BLFS's P/E ratio is -167.73. In terms of profitability, BDX's ROE is +0.04%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, BDX is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BLFS's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while KMTS trades at $27.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas KMTS's P/E ratio is -11.79. In terms of profitability, BDX's ROE is +0.04%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, BDX is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check KMTS's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while AZTA trades at $33.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas AZTA's P/E ratio is 79.95. In terms of profitability, BDX's ROE is +0.04%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, BDX is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AZTA's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while STAA trades at $24.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas STAA's P/E ratio is 42.26. In terms of profitability, BDX's ROE is +0.04%, compared to STAA's ROE of +0.01%. Regarding short-term risk, BDX is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STAA's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, QDEL has a market cap of 994.2M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while QDEL trades at $14.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas QDEL's P/E ratio is 10.88. In terms of profitability, BDX's ROE is +0.04%, compared to QDEL's ROE of -0.55%. Regarding short-term risk, BDX is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for BDX.Check QDEL's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ATRI trades at $459.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDX's ROE is +0.04%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BDX is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ATRI's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ANGO has a market cap of 647.7M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ANGO trades at $15.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ANGO's P/E ratio is -40.18. In terms of profitability, BDX's ROE is +0.04%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BDX is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ANGO's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, NNNN has a market cap of 372.4M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while NNNN trades at $8.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas NNNN's P/E ratio is 122.62. In terms of profitability, BDX's ROE is +0.04%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BDX is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NNNN's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, SMTI has a market cap of 313.9M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while SMTI trades at $34.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas SMTI's P/E ratio is -569.17. In terms of profitability, BDX's ROE is +0.04%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, BDX is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BDX.Check SMTI's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, OSUR has a market cap of 262.3M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while OSUR trades at $3.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas OSUR's P/E ratio is -6.93. In terms of profitability, BDX's ROE is +0.04%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, BDX is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check OSUR's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, INFU has a market cap of 246M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while INFU trades at $12.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas INFU's P/E ratio is 29.73. In terms of profitability, BDX's ROE is +0.04%, compared to INFU's ROE of +0.15%. Regarding short-term risk, BDX is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BDX.Check INFU's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, UTMD has a market cap of 223.6M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while UTMD trades at $70.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas UTMD's P/E ratio is 20.77. In terms of profitability, BDX's ROE is +0.04%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check UTMD's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, PDEX has a market cap of 214.4M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while PDEX trades at $67.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas PDEX's P/E ratio is 23.64. In terms of profitability, BDX's ROE is +0.04%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BDX is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check PDEX's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, KRMD has a market cap of 154.3M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while KRMD trades at $3.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas KRMD's P/E ratio is -84.00. In terms of profitability, BDX's ROE is +0.04%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, BDX is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check KRMD's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, MBOT has a market cap of 68.8M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while MBOT trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas MBOT's P/E ratio is -5.81. In terms of profitability, BDX's ROE is +0.04%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BDX is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MBOT's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while AKYA trades at $1.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BDX's ROE is +0.04%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BDX is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BDX.Check AKYA's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, DXR has a market cap of 59.5M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while DXR trades at $10.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas DXR's P/E ratio is 26.68. In terms of profitability, BDX's ROE is +0.04%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BDX is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for BDX.Check DXR's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while STSS trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas STSS's P/E ratio is -0.02. In terms of profitability, BDX's ROE is +0.04%, compared to STSS's ROE of -1.54%. Regarding short-term risk, BDX is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STSS's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while OMIC trades at $20.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDX's ROE is +0.04%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BDX is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BDX.Check OMIC's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while IGAP trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDX's ROE is +0.04%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, BDX is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for BDX.Check IGAP's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, NEPH has a market cap of 46.9M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while NEPH trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas NEPH's P/E ratio is 72.00. In terms of profitability, BDX's ROE is +0.04%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, BDX is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NEPH's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, POCI has a market cap of 45.7M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while POCI trades at $4.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas POCI's P/E ratio is -5.81. In terms of profitability, BDX's ROE is +0.04%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BDX is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check POCI's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, MLSS has a market cap of 43.2M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while MLSS trades at $0.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas MLSS's P/E ratio is -8.13. In terms of profitability, BDX's ROE is +0.04%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, BDX is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MLSS's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, HBIO has a market cap of 29.3M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while HBIO trades at $6.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas HBIO's P/E ratio is -18.06. In terms of profitability, BDX's ROE is +0.04%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, BDX is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check HBIO's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while SDC trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.04%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDX is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check SDC's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ZJYL has a market cap of 27.1M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ZJYL trades at $3.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ZJYL's P/E ratio is 21.63. In terms of profitability, BDX's ROE is +0.04%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ZJYL's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while IVC trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDX's ROE is +0.04%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDX is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check IVC's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, RVP has a market cap of 21M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while RVP trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas RVP's P/E ratio is -2.12. In terms of profitability, BDX's ROE is +0.04%, compared to RVP's ROE of -0.05%. Regarding short-term risk, BDX is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RVP's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, RGNT has a market cap of 14.1M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while RGNT trades at $2.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas RGNT's P/E ratio is -0.08. In terms of profitability, BDX's ROE is +0.04%, compared to RGNT's ROE of N/A. Regarding short-term risk, BDX is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RGNT's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, FEMY has a market cap of 6.5M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while FEMY trades at $2.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas FEMY's P/E ratio is -5.97. In terms of profitability, BDX's ROE is +0.04%, compared to FEMY's ROE of -2.16%. Regarding short-term risk, BDX is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check FEMY's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while NSTG trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.04%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDX is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NSTG's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, LUCY has a market cap of 4.4M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while LUCY trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas LUCY's P/E ratio is -0.41. In terms of profitability, BDX's ROE is +0.04%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, BDX is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LUCY's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while POAI trades at $4.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas POAI's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.04%, compared to POAI's ROE of -21.19%. Regarding short-term risk, BDX is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check POAI's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, NXGL has a market cap of 3.2M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while NXGL trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas NXGL's P/E ratio is -0.96. In terms of profitability, BDX's ROE is +0.04%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, BDX is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NXGL's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, GCTK has a market cap of 2.7M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while GCTK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas GCTK's P/E ratio is -0.02. In terms of profitability, BDX's ROE is +0.04%, compared to GCTK's ROE of -11.14%. Regarding short-term risk, BDX is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for BDX.Check GCTK's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while MHUA trades at $7.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BDX's ROE is +0.04%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BDX is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BDX.Check MHUA's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, NXGLW has a market cap of 1.9M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while NXGLW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, BDX's ROE is +0.04%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, BDX is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for BDX.Check NXGLW's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while GMVD trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDX's ROE is +0.04%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDX is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check GMVD's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while GMVDW trades at $7.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.04%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDX is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BDX.Check GMVDW's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while AVGR trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDX's ROE is +0.04%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BDX is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AVGR's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while LUCYW trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.04%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, BDX is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LUCYW's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ATRS trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDX's ROE is +0.04%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDX is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ATRS's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while APR trades at $37.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas APR's P/E ratio is 22.59. In terms of profitability, BDX's ROE is +0.04%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDX is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BDX.Check APR's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while HRC trades at $155.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDX's ROE is +0.04%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDX is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BDX.Check HRC's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while IIN trades at $24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDX's ROE is +0.04%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDX is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BDX.Check IIN's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while ALOG trades at $83.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BDX's ROE is +0.04%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BDX is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ALOG's competition here

Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BDX stands at 50.2B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BDX is priced at $182.09 on the NYSE, while IVTY trades at $7.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BDX currently has a P/E ratio of 14.01, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BDX's ROE is +0.04%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BDX is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BDX.Check IVTY's competition here